The Effects of Moxifloxacin and Gemifloxacin on the ECG Morphology in Healthy Volunteers: A Phase 1 Randomized Clinical Trial

Autor: Abid Ullah, Shujaat Ahmad, Niaz Ali, Haya Hussain, Mamdouh Allahyani, Mazen Almehmadi, Ahad Amer Alsaiari, Osama Abdulaziz, Feras Almarshad, Syeda Hajira Bukhari

Publikováno v: Diagnostics, Vol 13, Iss 7, p 1234 (2023)

Moxifloxacin and gemifloxacin are the two newer broad-spectrum 8-methoxy-quinolone derivatives that are used to treat various bacterial infections in cardiac patients. In this research study, we assessed the impact of moxifloxacin and gemifloxacin on

Externí odkaz: https://doaj.org/article/281bc1867c3742c6844c5798afc21bc8

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Autor: Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schöffski

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)

Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tum

Externí odkaz: https://doaj.org/article/c2fbc142a7e5490699bc7de71158c8cb

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Autor: Patrick Schöffski, Sandip Pravin Patel, Courtney Beers, Ben Tran, Richard D. Carvajal, Patricia LoRusso, Vijay V. Upreti, Erik Rasmussen, Gloria Juan, Aurélien Marabelle, Gataree Ngarmchamnanrith

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)

BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b9f62f8ee71a1a364d9591f41e7da8c
https://pubmed.ncbi.nlm.nih.gov/30253804

KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers

Autor: Fabio Badilini, Lucas Van Bortel, Brant Delafontaine, Saskia Koene, Griet Van Lancker, Edwin Spaans, Jan A.M. Smeitink, Julien Beyrath

Publikováno v: Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-12 (2017)
Orphanet Journal of Rare Diseases, 12, 1, pp. 163
Orphanet Journal of Rare Diseases, 12, 163
Orphanet Journal of Rare Diseases
ORPHANET JOURNAL OF RARE DISEASES

Background Mitochondrial disorders are a clinically, biochemically and genetically heterogeneous group of multi-system diseases, with an unmet medical need for treatment. KH176 is an orally bio-available small molecule under development for the treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6def6070fe39a944df84132e495d487a
https://doi.org/10.1186/s13023-017-0715-0